| Literature DB >> 28298639 |
Hung-Sheng Chen1,2, Chia-Yi Hsu2, Yu-Chia Chang1, Hui-Yu Chuang2, Cheng-Yu Long2, Tsung-Hua Hsieh3, Eing-Mei Tsai4,5,6,7,8.
Abstract
Phthalate, an environmental toxin, has been considered as an endocrine-disrupting chemical. Growing evidence has demonstrated links between endocrine-disrupting chemicals, tissue development, and reproductive physiology, but the mechanisms of gene expression regulation by environmental factors that affect cell differentiation are unclear. Herein, we investigated the effects of butyl benzyl phthalate (BBP) on human endometrial mesenchymal stem/stromal cell (EN-MSC) differentiation and identified a novel signaling pathway. Differentiation of endometrial mesenchymal stem/stromal cells decreased after administration of BBP. We analyzed BBP regulation of gene expression in EN-MSC using cDNA microarrays and Ingenuity Pathway Analysis software to identify affected target genes and their biological functions. PITX2 emerged as a common gene hit from separate screens targeting skeletal and muscular disorders, cell morphology, and tissue development. BBP decreased transcription of PITX2 and elevated expression of the microRNA miR-137, the predicted upstream negative regulator of PITX2. These data indicated that BBP affects PITX2 expression through miR-137 targeting of the 3' untranslated region of PITX2 mRNA. PITX2 down-regulation also decreased MyoD transcript levels in EN-MSC. Our results demonstrate that BBP decreases EN-MSC myogenic differentiation through up-regulation of miR-137, contribute to our understanding of EN-MSC differentiation, and underline the hazardous potential of environmental hormones.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28298639 PMCID: PMC5428022 DOI: 10.1038/s41598-017-00286-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Effect of BBP on EN-MSC differentiation. (A) EN-MSCs were cultured in differentiation medium for 2 weeks and treated with or without 1 μM BBP every day. Staining and magnification were carried out as in (A). Differentiation is apparent in control differentiation samples, whereas there is signal reduction in the BBP-treated differentiation samples. (B) Gene expression analysis of myogenic markers in differentiated EN-MSCs by real-time PCR analysis. Expression was analyzed with qPCR, using 18S as an internal control. The BBP treatment protocol was as in (A). (C) The RNA extraction and PCR to detect the level of endometrial MSC markers SUSD2. The data shown represent the mean ± SD of three experiments with three different batches of cells. *P < 0.05.
Top 15 BBP-downregulated genes.
| No. | Symbol | Fold change | Gene description |
|---|---|---|---|
| 1. |
| −130.750 | solute carrier family 5, member 12 |
| 2. |
| −44.673 | teratocarcinoma-derived growth factor 1 |
| 3. |
| −39.616 | ALX homeobox 1 |
| 4. |
| −35.254 | Variable Charge, Y-Linked/Variable Charge, Y-Linked1B |
| 5. |
| −32.750 | leucine-rich repeat LGI family, member 3 |
| 6. |
| −32.254 | collagen, type IX, alpha 3 |
| 7. |
| −31.313 | annexin A13 |
| 8. |
| −20.607 | alcohol dehydrogenase 4 (class II), pi polypeptide |
| 9. |
| −18.950 | bromodomain and WD repeat domain containing 1 |
| 10. |
| −18.920 | membrane-spanning 4-domains, subfamily A, member 1 |
| 11. |
| −4.42 | Synovial Sarcoma, X Breakpoint 3 |
| 12. |
| −0.109 | visual system homeobox 1 |
| 13. |
| −0.258 | Zic family member 3 |
| 14. |
| −0.387 | interleukin 13 |
| 15. |
| −0.390 | protein tyrosine phosphatase, receptor type, C |
Functional description of candidate genes responsible for BBP regulation of EN-MSCs.
| Skeletal and Muscular Disorders | Cell Morphology | Tissue Development | |||
|---|---|---|---|---|---|
| Symbol | Gene description | Symbol | Gene description | Symbol | Gene description |
|
| ALX homeobox 1 |
| acid-sensing (proton-gated) ion channel 2 |
| ADAM metallopeptidase domain 28 |
|
| caspase 1, apoptosis-related cysteine peptidase |
| beta-carotene 15,15′-monooxygenase 1 |
| ALX homeobox 1 |
|
| caspase 192 |
| caspase 1, apoptosis-related cysteine peptidase |
| cadherin 1, type 1, E-cadherin (epithelial) |
|
| chemokine (C-C motif) ligand 23 |
| cadherin 1, type 1, E-cadherin (epithelial) |
| cadherin 24, type 2 |
|
| cadherin 1, type 1, E-cadherin (epithelial) |
| estrogen-related receptor gamma |
| GLIS family zinc finger 3 |
|
| checkpoint kinase 2 |
| ghrelin/obestatin prepropeptide |
| homeodomain interacting protein kinase 1 |
|
| cholinergic receptor, muscarinic 2 |
| GLIS family zinc finger 3 |
| hyaluronoglucosaminidase 1 |
|
| collagen, type IX, alpha 3 |
| immunoglobulin lambda-like polypeptide 1 |
| LIM homeobox 9 |
|
| Fas ligand (TNF superfamily, member 6) |
| kinesin family member 18 |
| orthodenticle homeobox 1 |
|
| glycophorin A (MNS blood group) |
| myotubularin related protein 3 |
| ovo-like 1 (Drosophila) |
|
| homeodomain interacting protein kinase 1 |
|
|
| paired-like homeodomain 2 |
|
| hyaluronoglucosaminidase 1 |
| paired-like homeodomain 2 |
| prostaglandin E receptor 3 (subtype EP3) |
|
| potassium voltage-gated channel, Isk-related family, member 3 |
| prostaglandin E receptor 3 (subtype EP3) |
| protein tyrosine phosphatase, receptor type, C |
|
| potassium inwardly-rectifying channel, subfamily J, member 15 |
| protein tyrosine phosphatase, receptor type, C |
| regulator of G-protein signaling 3 |
|
|
|
| regulator of G-protein signaling 3 |
| v- |
|
| membrane-spanning 4-domains, subfamily A, member 1 |
| v- |
| transcription factor 12 |
|
| orthodenticle homeobox 1 |
| toll-like receptor 2 |
| teratocarcinoma-derived growth factor 1 |
|
| phosphatase and actin regulator 3 |
| zona pellucida glycoprotein 3 (sperm receptor) |
| toll-like receptor 2 |
|
| paired-like homeodomain 2 |
| WW domain containing oxidoreductase | ||
|
| protein tyrosine phosphatase, receptor type, C |
| zona pellucida glycoprotein 3 (sperm receptor) | ||
|
| solute carrier family 22 (organic anion/urate transporter), member 12 | ||||
|
| v- | ||||
|
| toll-like receptor 2 | ||||
|
| ? | ||||
|
| WW domain containing oxidoreductase | ||||
|
| zinc finger protein | ||||
Figure 2mRNA levels of the three identified genes. (A) Venn diagram with the number of genes differentially expressed between biofunctions in three individual categories: skeletal and muscular disorders, cell morphology, and tissue development. The shaded area shows intersection of all three categories and denotes three shared genes that emerged: PITX2, SRC, and TLR2. (B) qRT-PCR analysis of mRNA levels of the three identified genes; all genes showed significant reduction in expression after BBP treatment as compared with controls. (C) The level of miR-137 was increased in BBP-treated EN-MSCs compared with control cells. U6 was detected as an internal control. (D) Validation of miR-137 target. Precursor-miR-137 effectively decreased the transcript level of PITX2. The data shown represent the mean ± SD of three experiments with three different batches of cells. *P < 0.05.
Figure 3PITX2 mRNA is a direct target of miR-137. (A) Sequences of target sites for miR-137 in the wild-type and mutant (Mut) versions of 3′-UTR of PITX2 mRNA. (B) Cells were co-transfected with precursor-miR-137 or precursor control and the pGL2 vector containing wild-type (Wt) or mutant version of the putative PITX2 3′UTR miR-137 binding site. Luciferase activity was normalized to the control. (C) Western blot analysis was used to detect the expression of MyoD and PITX2 in response to miR-137 alteration. (D) EN-MSCs were cultured in differentiation medium for 2 weeks and transected with miR-137. Gene expression analysis of myogenic markers in differentiated EN-MSCs by real-time PCR analysis. Expression was analyzed with qPCR, using 18S as an internal control. The data shown represent the mean ± SD of three experiments with three different batches of cells. *P < 0.05.
Figure 4Knockdown and overexpression of PITX2 affect MyoD expression. (A) EN-MSCs transfected with PITX2 shRNA-1, PITX2 shRNA-2 or scrambled shRNA (a negative control for PITX2 shRNA). (B) qPCR analysis of mRNA levels of MyoD. Expression levels were normalized to 18S rRNA levels. (C) EN-MSCs were transfected with PITX2 or control vector. qPCR analysis of mRNA levels of PITX2. (D) mRNA levels of MyoD were analyzed with qPCR. Expression levels were normalized to 18S rRNA levels. (E) Western blotting indicated that PITX2 and MyoD level were positively correlated. The data shown represent the mean ± SD of three experiments with three different batches of cells. *P < 0.05.